- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04743856
The Clinical Referral to Activity Study
Advancement of Clinical Referral to Physical Activity for Cardiometabolic Disease Prevention
Study Overview
Status
Intervention / Treatment
Detailed Description
The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes 13 weekly and 6 monthly social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year.
A total of n=54 Clinical care patients aged 40-70 years of age with low physical activity (PA) levels (<150 minutes/week) at risk for cardiovascular disease will be recruited. Study outcomes will be measured at baseline, 6 months after intervention start and 12 months after intervention start.
For the primary outcomes, the investigators hypothesize that participants randomized to ActiveGOALSv2 + PAT will have significantly larger (a) increases in step counts/day and % meeting moderate-vigorous physical activity goal of 150 minutes/week (to 12 months) compared to the active PAT control group. Descriptive analyses and graphic displays will be used to identify outliers, missing data, and pattern of attrition. To ensure rigor, the primary analytic strategy will be a linear or generalized mixed-effect models approach in which treatment group, time, and time by group interaction are treated as fixed effects, and subject is treated as a random effect to account for individual subject variability (two sided hypothesis test; .05 level). Mixed models are applicable to longitudinal datasets that contain missing observations, (assuming data is missing at random). Regression modeling will be conducted to adjust for important covariates. The investigators will perform similar analyses to examine changes in secondary outcomes. Descriptive statistics on patient experience, beliefs/attitudes related to maintenance of physical activity changes, and program cost will also be reported.
Power and sample size: For a 2 sided test with alpha level set at .05, and assuming 20% attrition at 12 months, the investigators plan to recruit 54 participants to identify clinically relevant mean difference between randomized groups at 12-months of 2000 steps/day (with a power of .80), and 35% meeting MVPA goal (with a power of .80), given reference mean (sd) values were calculated from baseline waist worn accelerometer data from the current K12 of: 5250 (2200) steps/ day and the investigators assume 5% meeting goal at baseline in the control group.
Descriptive statistics will be used to describe the total eligible population, those referred, and those referred who participated in the study; in order to determine program reach. Exploratory Analysis of Important Pre-Existing Factors: Factor analysis will be used to identify importance of factors related to physical activity levels/ activity goal achievement over the 12 month follow-up (Mplus) from participant EHR data collected prior to intervention start. Factor structures of how individual factors contribute to activity outcomes will be explored at each time point. The best factor structure will be determined with Eigenvalues and fit indices (RMSEA, CFI, and TLI). Factor structures at the 2 time points will be compared at three levels to establish measurement invariance: 1) Configural equivalence, number of factors/ pattern of factor-indicator relationships are identical over time; 2) Metric equivalence, factor loadings are equal over time; and 3) Scalar equivalence, means and values are equivalent over time. Finally, the investigators will use descriptive statistics to report presence/absence of data on physical activity levels, cardiometabolic, and patient-centered outcomes in the EHR. The investigators will apply the same regression approaches utilized in Aim 1a to determine differences between randomized groups for EHR reported outcomes.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bonny Rockette-Wagner, PhD
- Phone Number: (412) 624-0118
- Email: bjr26@pitt.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15261
- Recruiting
- University of Pittsburgh
-
Contact:
- Bonny Rockette-Wagner, PhD
- Phone Number: 412-624-0188
- Email: bjr26@pitt.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 40-70 years of age
- Low physical activity (PA) levels (<150 minutes/week)
At least one of the following common cardiometabolic risk factors:
- high blood pressure:> 129 mm hg SP or >89 mm hg DP or medication
- high fasting glucose:>100 mg/dl or high HbA1c: ≥42 mmols/mol or medication
- overweight/ obesity: BMI ≥25 kg/m2).
- Have access to the internet
- Able to read English at a 6th grade level
- Have primary care provider (PCP) permission to increase physical activity without supervision.
Exclusion Criteria:
- Have participated in a physical activity intervention program with behavior tracking and goal setting in the past year.
- Told by a physician that they have diabetes (other than previous gestational diabetes) or have received a diagnosis of cardiovascular disease, regardless of when.
- Pregnant or planning a pregnancy in <12 months
- Non-ambulatory or planning a procedure that will lead to not being ambulatory in <12 months.
- Women who become pregnant during the study will be required to get an updated referral form from their primary care provider (PCP) stating that they are able to increase their physical activity without supervision .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PAT (Physical activity monitor)
Participants will receive a physical activity tracker and encouragement to increase physical activity.
|
Participants will receive a physical activity tracker and encouragement to increase activity.
|
Experimental: ActiveGOALSv2
Participants will receive the ActiveGOALS online program with an integrated activity tracker.
|
13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support.
Once a month support materials sent monthly from months 4-12 of intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in meeting the aerobic activity goal at 12 months
Time Frame: 12 months versus baseline
|
Change between 0 and 12 months for y/n meeting the 150 minute/week moderate-vigorous activity goal based on minutes of activity from accelerometer
|
12 months versus baseline
|
Change from baseline in Step counts at 12 months
Time Frame: 12 months versus baseline
|
Objectively measured change in step counts between 0 and 12 months using ActiGraph accelerometer
|
12 months versus baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sedentary behavior minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
|
Objectively measured sedentary behavior over all timepoints for 12 months using ActiGraph accelerometer
|
1 week recording; measured at baseline, 6 and 12 months
|
Moderate-vigorous activity minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
|
Objectively measured moderate-vigorous activity over all timepoints for 12 months using ActiGraph accelerometer
|
1 week recording; measured at baseline, 6 and 12 months
|
Light activity minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
|
Objectively measured Light activity over all timepoints for 12 months using ActiGraph accelerometer
|
1 week recording; measured at baseline, 6 and 12 months
|
Step counts over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
|
Objectively measured Step counts over all timepoints for 12 months using ActiGraph accelerometer
|
1 week recording; measured at baseline, 6 and 12 months
|
Patient experience
Time Frame: measured at 6 and 12 months
|
patient experience survey designed for this study with the help of patient partners to gather feedback from participants.
Feedback will be used in the development of future interventions
|
measured at 6 and 12 months
|
Blood Pressure over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
Taken by trained clinic staff using a validated automated blood pressure cuff after participant is seated in an upright position for 5 minutes.
Two measure will be taken and the average of the two measures will be used.
If the measures are not within 5 mmHG, a third measure will be taken.
|
measured at baseline, 6 and 12 months
|
Body Weight over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
will be measured in clinic by trained staff using a validated scale.
Participants will be asked to take shoes off and wear light clothes.
Average of two measures will be used; if weight is more than .5 pounds different, a third will be taken.
|
measured at baseline, 6 and 12 months
|
Waist Circumference over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
will be measured above the iliac crest in clinic by trained staff.
Two measures will be taken and averaged; if measures are more than 1 cm different a third measure will be taken.
|
measured at baseline, 6 and 12 months
|
Fasting Blood Glucose over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
HbA1c over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
LDL Cholesterol over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
HDL Cholesterol over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
Perceived Health Score over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
EuroQAL Visual Analogue Scale (EQ-VAS)-Self-reported perception of health on a 0 (lowest possible) to 100 (highest possible) scale.
|
measured at baseline, 6 and 12 months
|
Insulin over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
Triglycerides over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
|
A fasting blood draw will be taken after 12-16 hours fast.
|
measured at baseline, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bonny Rockette-Wagner, PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20030079
- 1K01HL151668-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on PAT
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
Wake Forest University Health SciencesCompletedChronic Toxic Stress | Developmental/ Behavioral Regression in Young ChildrenUnited States
-
IWK Health CentreMayday FundCompleted
-
Nationwide Children's HospitalEnrolling by invitationProcedural Pain | Procedural AnxietyUnited States
-
Wonju Severance Christian HospitalDong-A ST Co., Ltd.CompletedObstructive Sleep Apnea | Acute Myocardial InfarctionKorea, Republic of
-
Meir Medical CenterUnknownSymptomatic Congestive Heart FailureIsrael
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
IWK Health CentreMayday FundCompletedPediatric Pain and AnxietyCanada
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Pregnancy | Weight GainUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnPrimary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential ThrombocythemiaUnited States